Stock Detail
REGENERON PHARMACEUTICALS INC
Biotechnology
REGN @ Yahoo Finance | REGN Option @ Yahoo Finance
Last Day's Data
| Current Price | High | Value Change | Percent Change | Dividend | Previous Close |
|---|---|---|---|---|---|
| $50.74 | $52.85 | $-2.20 | -4.16% | 0.00 | $52.94 |
| Opening Price | Low | Volume | Market Cap | Average Volume | P/E |
| $52.82 | $50.53 | 945,440 | 4.7B | 1.34M | -25.00 |
Pivot Table
| R2 | R1 | Pivot | S1 | S2 |
| 53.69 | 52.21 | 51.37 | 49.89 | 49.05 |
Stock Profile
Regeneron Pharmaceuticals, Inc. engages in the discovery and development of pharmaceutical products for the treatment of human disorders and conditions. Its clinical and preclinical pipeline includes product candidates for the treatment of cancer, diseases of the eye, rheumatoid arthritis, and other inflammatory conditions like allergies, asthma, and other diseases and disorders. The company primarily focuses on the development of the VEGF Trap in oncology and eye diseases, which are in phase I clinical trails; and the IL (Interleukin)-1 Trap in various indications in, which interleukin-1 plays a role, including rheumatoid arthritis and other inflammatory conditions. VEGF TRAP is a protein-based product candidate designed to bind Vascular Endothelial Growth Factor (VEGF) and the related Placental Growth Factor, and prevent their interaction with cell surface receptors. Interleukin-1 Trap, which is in preclinical stage, is a protein-based product candidate designed to bind the interleukin-1 cytokine and prevent its interaction with cell surface receptors used for the treatment of diseases associated with inflammation in blood vessels. IL-1 Trap is in phase 2b study for its use in rheumatoid arthritis in a double blind, placebo-controlled, and multicenter trial. Regeneron's product candidates in preclinical development stage include Interleukin-4/Interleukin-13 Trap, a protein-based product candidate designed to bind both the interleukin-4 and interleukin-13, which is used for the treatment of diseases, such as asthma, allergic disorders, and other inflammatory diseases. The company also provides contract manufacturing services for the production of an intermediate for a pediatric vaccine. Regeneron has collaboration and licensing agreements with sanofi-aventis Group, Novartis Pharma AG, and The Procter & Gamble Company. The company was founded by Leonard S. Schleifer in 1988. Regeneron is headquartered in Tarrytown, New York.